{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:31:26Z","timestamp":1776745886862,"version":"3.51.2"},"reference-count":24,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T00:00:00Z","timestamp":1536624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Jehovah's Witnesses pose a clinical challenge in the setting of critical anemia. Most do not accept transfusions, but some accept hemoglobin\u2010based oxygen carriers on a compassionate\u2010use basis. PEGylated carboxyhemoglobin bovine (PCHB) is an acellular dual\u2010action carbon monoxide (CO)\u2010releasing and oxygen transfer agent currently being investigated in Phase II clinical trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>CASE REPORT<\/jats:title><jats:p>We present the case of a 42\u2010year\u2010old Jehovah's Witness with an acute upper gastrointestinal bleed and hemorrhagic shock who required emergent PCHB for stabilization during lifesaving interventions. After PCHB infusion, the patient's shock and encephalopathy improved with decreased vasopressor requirement. Through gastroenterology and interventional radiology procedures, the patient's bleeding stabilized. While receiving five additional doses of PCHB and other supportive therapies (iron, folate, vitamin B12, darbepoetin alfa), the patient was extubated and weaned off vasopressors.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>PCHB was used to stabilize (bridge) a critically ill anemic patient for lifesaving interventions without adverse effects. Additional studies are warranted to explore the drug's safety profile and efficacy in patients declining blood products.<\/jats:p><\/jats:sec>","DOI":"10.1111\/trf.14799","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T10:04:11Z","timestamp":1536660251000},"page":"2297-2300","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Investigational use of PEGylated carboxyhemoglobin bovine in a Jehovah's Witness with hemorrhagic shock"],"prefix":"10.1111","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3484-790X","authenticated-orcid":false,"given":"Robert A.","family":"DeSimone","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Berlin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Pulmonary and Critical Care Medicine New York\u2010Presbyterian Hospital\u2010Weill Cornell Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott T.","family":"Avecilla","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Memorial Sloan Kettering Cancer Center  New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl A.","family":"Goss","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Memorial Sloan Kettering Cancer Center  New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,9,11]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1981.03320210037021"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/jme.25.6.469"},{"key":"e_1_2_5_4_1","first-page":"463","article-title":"Blood: whose choice and whose conscience?","volume":"88","author":"Dixon JL.","year":"1988","journal-title":"N Y State J Med"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00123.x"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12565"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12424"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12888"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200002000-00022"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjaceaccp\/mks025"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/TA.0000000000000204"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1590\/S1807-59322009000800016"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.19.jrv80007"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118074"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2000.4167"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118102"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.13.1653"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13607"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2012.4922"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/aor.12341"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.3109\/21691401.2012.762370"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2015.06.011"},{"key":"e_1_2_5_23_1","unstructured":"A study of SANGUINATE for the treatment of vaso\u2010occlusive crisis (VOC) in adult sickle cell disease patients [Internet]. Bethesda:ClinicalTrials.gov;2016[cited 2018 Feb 2]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02672540."},{"key":"e_1_2_5_24_1","unstructured":"Study of SANGUINATETMin the treatment of sickle cell disease patients with vaso\u2010occlusive crisis [Internet]. Bethesda:ClinicalTrials.gov;2015[cited 2018 Feb 2]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02411708."},{"key":"e_1_2_5_25_1","unstructured":"Study to assess the safety and impact on humoral sensitization of SANGUINATE in patients with end stage renal disease [Internet]. Bethesda:ClinicalTrials.gov;2015[cited 2018 Feb 2]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02437422."}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftrf.14799","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.14799","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T11:47:11Z","timestamp":1694864831000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.14799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,11]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1111\/trf.14799"],"URL":"https:\/\/doi.org\/10.1111\/trf.14799","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,11]]},"assertion":[{"value":"2018-02-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}